Notice of Clarification to PAR-18-841, "Oncology Co-Clinical Imaging Research Resources to Encourage Consensus on Quantitative Imaging Methods and Precision Medicine (U24 - Clinical Trial Optional)"

Notice Number: NOT-CA-19-064

Key Dates
Release Date: July 24, 2019

Related Announcements
PAR-18-841

Issued by
NATIONAL CANCER INSTITUTE (NCI)

Purpose

This Notice clarifies and reiterates the types of cancers that are appropriate for co-clinical trials in PAR-18-841 “Oncology Co-Clinical Imaging Research Resources to Encourage Consensus on Quantitative Imaging Methods and Precision Medicine (U24 - Clinical Trial Optional)”.

The following text (in italics) has been added to:

Part 2. Full Text of Announcement, Section I. Funding Opportunity Description

Purpose

Currently reads:

The purpose of this Funding Opportunity Announcement (FOA) is to invite Cooperative Agreement applications to develop research resources that will encourage a consensus on how Quantitative Imaging (QI) methods are optimized to improve the quality of imaging results for co-clinical trials.

Modified to read (in italics):

The purpose of this Funding Opportunity Announcement (FOA) is to invite Cooperative Agreement applications to develop research resources that will encourage a consensus on how Quantitative Imaging (QI) methods are optimized to improve the quality of imaging results for co-clinical trials of adult and/or pediatric cancers.

All other aspects of PAR-18-841 remain unchanged.

Inquiries

Please direct all inquiries to:

Huiming Zhang, Ph.D.
National Cancer Institute (NCI)
Telephone: 240-276-5979
Email: zhanghui@mail.nih.gov